Member Info for AquaeSulis01

Bazza, like here, the only people that know how things are really going is the Croda management and they have been buying. I have bought Croda at these low levels as a long term dividend stock, with the first qualifying payment starting later this month.

From the April 25 Inv Meets "Croda Global Launch

o Zenakine launched 8/4/25

o “Gamechanger’ of a

product

o Excellent feedback from

attendees

o Very high expectations

internally at Sederma"

So hopefully the RNS is telling us that Sederma's very high expectations are being met

All wasps can sting. Time will tell whether the sting has landed in this case.

So it was just noise that caused "Resolution 5, a Special Resolution which sought to give the Directors power to issue new ordinary shares for cash other than to the Company's shareholders on a pro rata basis, was not passed"?

Bazzaman, at last a useful contribution from you, cheers. I haven't been tracking the Croda price so you pointing out the latest pullback has prompted me to buy some shares because you are right, most of the Investing world does not know about the blockbuster that sits under the radar.

Not the highest bar in the world; sweetbiotix to be launched sometime in the next 10 years then?

"The New Options expire on 6 August 2035 with 269,079 of the New Options vesting on the first anniversary of the options being granted being 6 August 2026 and the balance (comprising 89,693 New Options) vesting once the Company signs a commercial agreement with a partner providing equal or greater than £100k revenues per annum for products containing SweetBiotix.

The issue of the New Options follows the expiration of 358,772 options of ordinary shares granted to Sofia Kolyda which expired in March 2025 of which 75% had vested."

WIILG, think you need to read through some of the Skinbiotherapeutic patents to see the full extent of the wound healing aspects including ulcers.

"We have identified a strain of probiotic bacterium (L rhamnosus GG) with skin cell protecting and regenerative properties. Significantly, lysates of this strain improve skin keratinocytes ability to resist harmful toxicity induced by S, aureus. When used in combination with another strain (L reuteri) the combination is even more effective at protecting against S. aureus than when either strain is used alone. We have also demonstrated that when keratinocyte monolayers are scratched to remove cells (model wound) the presence of our propriety probiotic lysates significantly and surprisingly speeds up the recovery of the monolayer and re-establishment of the barrier. "

https://ppubs.uspto.gov/api/pdf/downloadPdf/20170196919?requestToken=eyJzdWIiOiJlYWI1MmExMC05ZjkxLTQxOGItYWUyNS0zZWNiZTAyYzI4MDIiLCJ2ZXIiOiIzODBlNjU0NC01ZDA5LTQzYTMtODFkNy04YmU0N2RiOTNlYTgiLCJleHAiOjB9

WIILG, whilst Croda royalty money will in time become the major contributor to profit in the not too distant future, the exam question was about the upcoming revenue figures and whether the Singer note understated them. To that end Dermatonics is expected to hit £2.91m (thanks to an uplift from the US and India), Bio-Tech Solutions will contribute £2m, and Axis £400k providing £5.3M in total for 2025 (a figure greater than the Singer note). On top of this will be Croda Royalty revenue guesstimated between £200k - £500K.

I therefore hoped to demonstrate that Dermatonics was likely on track to meet its target via the geographical expansion in USA on top of India where similar sales of the pheet heel balm through clinics goes under the visible internet radar.

I would also not write off to both acquisitions playing their part in future growth; skinbiotix incorporated into dermatonics clinical products such as once heel balm would provide a cure as well as a preventative for leg ulcers but admittedly is some way off,

However, just part of the story:

Amazon vs. Total U.S. Sales

Channel Estimated Monthly Units Revenue Estimate Notes

Amazon USA 1,500–2,000 ~$13,500–$22,000 Based on “bought in past month” tags across variants

Other Channels 13,500–23,000 ~$135,000–$278,000 Includes podiatry clinics, B2B distributors, direct site

That suggests Amazon accounts for roughly 6–12% of total U.S. sales, with the bulk coming from clinical and distributor networks. This aligns with Dermatonics’ positioning as a clinically endorsed brand, often recommended for diabetic foot care and ulcer prevention.

Clinical & Professional Channels

• Podiatry Clinics: Widely recommended for diabetic foot care and callus prevention. Clinical reviews highlight its use in managing neuropathy-related skin conditions.

• Hospital Networks: Trials at NHS Highland and Whittington (UK) have influenced adoption in U.S. diabetic foot care protocols.

• Healthcare Professionals: Promoted as a once-daily, high-urea emollient for ulcer prevention, aligning with NICE guidelines and diabetic foot screening practices.

📦 Distributor Channels

• Justin Blair & Company: Exclusive U.S. distributor for Dermatonics, supplying foot care retailers, clinics, and wholesalers.

• Algeos USA: Offers Dermatonics Once Heel Balm and other variants to clinical buyers and podiatry suppliers.

🛍️ Direct-to-Consumer Channels

• Dermatonics USA Website: Sells the full product range directly to consumers, often with bundle offers and seasonal promotions.

• Specialty Pharmacies: Select online pharmacies and wellness retailers stock Dermatonics balms, especially those targeting diabetic and dry skin needs.

• Justin Blair & Company was announced as the exclusive U.S. distributor for Dermatonics on November 5, 2024. The partnership introduced Dermatonics’ natural, clinically backed skincare range—including its heel balms—to the American market via professional and retail channels.

Well I'm with Toyin regarding the revenue under estimate by Singers. Must admit to being concerned that the Dermatonics USA re-launch may not of met expectations but that was because I was focused on Amazon sales:

Based on Amazon USA retail signals, Dermatonics Heel Balm appears to sell approximately 800–1,300 units per month per variant. Here's how that estimate shapes up:

🧴 Product-Level Indicators

• Manuka Honey Heel & Elbow Cream: Listed with “800+ bought in past month”.

• Hard Skin & Callus Removing Balm: Shows “500+ bought in past month”.

• Soothing Foot Cream: Around “100+ bought in past month”.

These figures reflect individual SKUs, so total monthly sales across all Dermatonics heel balm variants on Amazon USA likely fall in the range of 1,500–2,000 units.

Avg. price per unit ~$10.99–$12.99

Net revenue per unit ~$9–$11 (after fees/discounts)

Monthly revenue (Amazon) ~$13,500–$22,000

Interesting to see the research work the Croda speaker on zenadine, Dr Bhaven, has carried out with A McBain and Prof Cath O Neill in the area of the microbiome and sunscreen. https://www.researchgate.net/publication/371843604_Exploring_associations_between_skin_the_dermal_microbiome_and_ultraviolet_radiation_advancing_possibilities_for_next-generation_sunscreens

Nice find mol

Blimey, is it New Year's Eve already, don't know where the time goes these days?

If they weren't the overhang would of expected to have seen a few more TR1s by now

The actual wording at 21 mins in (thanks Toyin) is "one of our new super refined ingredients is an aid to cell culture media, which has been very fast -- we've seen a very fast uptake for a new product."

From the Zenakine Technical slides "Epidermis reinforcement

Zenakine promotes the neosynthesis of extracellular matrix components, stimulating skin regeneration. At 3 %, it increases the production of: - Collagen I by 36 % * and collagen IV by 67 %* - Fibronectin by +20 %* and laminins by 26 %*"

So posing the question to AI "Can something that promotes the neosynthesis of extracellular matrix components be described as an aid to cell culture media?" Response "Yes—with nuance. An ingredient that promotes the neosynthesis (i.e., new formation) of extracellular matrix (ECM) components—like collagen, elastin, or fibronectin—can be considered an “aid to cell culture media,” if it actively enhances cellular function relevant to your experimental goals.

But it depends on context and classification:

📌 When It Is Considered an Aid

- Functional Enhancement: If it improves fibroblast performance, ECM deposition, or cell-matrix interaction—especially in regenerative, dermal, or scaffold studies.

- Defined Application: Used deliberately to replicate or boost in vivo behavior (e.g. dermal fibroblast-mediated wound healing, ECM modeling).

- Compatible Format: Must be soluble, stable, and non-toxic in culture conditions.

Examples:

- Recombinant growth factors (e.g. TGF-β1) that boost collagen production.

- ECM-modulating peptides (e.g. GHK-Cu) that stimulate neosynthesis.

- Small molecules that upregulate MMP inhibitors to preserve ECM integrity"

So the conclusion is that we are talking Zenakine and it is in high demand

Lord, skid is correct, problem is with googling and AI is that you need to ask the right question; gross revenue is more a US Company term and not applicable under IFRS.

"Under IFRS, the official term is simply “revenue”, defined as the gross inflow of economic benefits arising in the ordinary course of business when those inflows result in increases in equity (excluding contributions from equity participants).

The phrase “gross revenue” isn’t formally defined in IFRS standards like IFRS 15 or IAS 18. However, it’s sometimes used informally or in management commentary to distinguish total revenue before deductions (like returns, discounts, or rebates) from “net revenue”. But in audited financial statements prepared under IFRS, the term “revenue” already refers to the gross amount unless the entity is acting as an agent, in which case only the net commission is recognized"

Cutting through the fluff:

Cash End Dec 2024 was £739K

Post Year End Placing £750K

Post Year End SBTX shares sold £500K

Cash End Jun 2025 was £1.3M

Net loss H1 2025 (£689K)

Net, you have to have been a LTH to appreciate why days have turned into years but here’s a flavour:

4 Dec 2020 Full Year Results RNS

The project is progressing in line with the original plan and has not been adversely impacted by COVID-19. On the basis of continued progress, the Company anticipates licensed royalty revenue generation to commence in 2022

30th Nov 2021 Full year Results RNS

Throughout this collaboration, Sederma has identified additional potential scientific and marketing claims for the end ingredient. The eventual claims will be an important component of the launch and long-term commercial success of the ingredient. To this end, Sederma is continuing its lab work to further substantiate these additional potential claims. This work is not impacting the manufacturing scale-up. The Group continues to anticipate 2022 as the period for initial royalty revenues.

29th Mar 2022 Half Year Reults RNS

Croda is engaging with its VIP clients about SkinBiotix as an active cosmetic ingredient; the Group continues to anticipate licensed royalty revenue generation by the end of 2022

15th Dec 2022 Full Year Results RNS

Partnership with Croda plc is in the product development stage, with timing controlled by Croda. Product launch expected to occur in 2023 which would trigger initial royalties revenues from Croda later in the calendar year

28th Mar 2023 HY Results RNS

Management continues to progress the partnership with Croda and anticipates that 2023 will see the commercial launch of the cosmetic ingredient.

30th Nov 2023 Full Year Results RNS

During this financial year, Sederma has been focused on developing quality formulations with their customers, which has seen scaling-up manufacture of SkinBiotix? from 600 litres to 2,000 litres which is expected to ultimately lead to the 20,000 litres vessel required to service the global market. 4 pilot batches have been manufactured which identified significant, unexpected technical benefits which Sederma believes may lead to a justifiable increase in price based on clinical evidence. To this end, the company extended its development agreement with Croda plc to allow a clinical trial to be carried out to evidence the additional activity. This study is fully funded by Sederma /Croda and is expected to be completed early 2024.

Post year end, in November, Sederma extended its contract with SkinBioTherapeutics for a further 12 months to conduct these studies which are due to run from late 2023 into early 2024.

..And here we are today awaiting revenue news

Net "A broker doesn't know any more than we do - its just their stab in the dark" suggest you ask your AI oracle whether a HOUSE Broker for a LSE listed Company should at least be as well informed as the LTHs rather than less

...but there is some hope for the future. bearing in mind:

" As of July 2025, Poppi has agreed to a proposed $8.9 million class action settlement to resolve allegations that it falsely advertised its prebiotic sodas as “gut healthy” despite containing only 2 grams of prebiotic fiber per can—too little to deliver meaningful digestive benefits.

🧾 Key Details of the Settlement

- Eligible Purchases: Any flavor or pack size of Poppi bought in the U.S. between Jan 23, 2020 and July 18, 2025

- Payouts:

- With proof of purchase: Up to $0.75 per can, $3 per 4-pack, $6 per 8-pack, $9 per 12- or 15-pack

- Without proof: Up to $16 per household, with a minimum of $5

- Claim Deadline: Sept 26, 2025

- Final Approval Hearing: Scheduled for Nov 20, 2025"

then Pepsi will no doubt be keen/under pressure to introduce a truly healthy pre-biotic brand which could be achieved by introducing a combination of slimbiome/wellbiome and sweetbiotix. From the last Investor Meets Q&A "We continue to make good progress on our range of SweetBiotix products with a number of well known brands and corporates. We are in a period of high commercial sensitivity and unfortunately have had to limit shareholder communication in this area due to a small number of shareholders contacting companies direct, often masquerading as OptiBiotix employees, to seek inside information. These are complex 3 way negotiations with a large corporate manufacturer (DSM Firmenich), some well known brands, and ourselves over long time periods further complicated with some partners now looking at Slimbiome and WellBiome given the growing interest in prebiotic drinks" so maybe not a pipedream after all